Search TBPH
Theravance Biopharma, Inc.
Nasdaq · CIK 1583107
Last close17.03
Daily changen/a
10 Years gain-52.40%
Dividends TTM0
Dividend yieldn/a
Fundamental Analysis
TBPH · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
86.6Momentum
100.0Acceleration
100.0Confidence
85.0Annual Revenue14
Quarterly Revenue66
Annual CFO11
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth24.6 / 25
Quality17.6 / 25
Capital Efficiency16.2 / 20
Balance Sheet15.0 / 15
Shareholder Economics8.9 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 44.1489 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Key Metrics
Revenue Growth TTM35.11%OK
Revenue CAGR 3Y27.91%OK
Gross Margin100%OK
Operating Margin-4.03%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Y111.47%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y1.86%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $107.46M | $107.46M | -$3.60M | $238.54M | $238.50M | 100% | -3.35% | 221.93% | -8.61% | 51.51M |
| 2025 FY Dec 31, 2024 | $64.38M | $64.38M | -$46.95M | -$11.54M | -$11.87M | 100% | -72.92% | -18.43% | -37.51% | 48.85M |
| 2024 FY Dec 31, 2023 | $57.42M | $57.42M | -$56.04M | -$27.00M | -$29.49M | 100% | -97.58% | -51.35% | -39.37% | 55.3M |
| 2023 FY Dec 31, 2022 | $51.35M | $51.35M | -$91.96M | -$186.99M | -$187.56M | 100% | -179.09% | -365.29% | -66.46% | 73.59M |
| 2022 FY Dec 31, 2021 | $55.31M | $55.31M | -$257.78M | -$207.86M | -$211.26M | 100% | -466.06% | -381.96% | -321.28% | 69.46M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $104.31M | sum latest 4 fiscal quarters Revenue | OK | 0001104659-26-033077, 0001104659-26-056760 |
| Revenue Growth TTM | 35.11% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001104659-26-033077, 0001104659-26-056760 |
| Revenue CAGR 3Y | 27.91% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001104659-26-033077 |
| Revenue CAGR 5Y | 8.38% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001104659-26-033077 |
| Gross Profit CAGR 3Y | 27.91% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001104659-26-033077 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001104659-26-033077, 0001104659-26-056760 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001104659-26-033077, 0001104659-26-056760 |
| Operating Margin | -4.03% | Operating Income / Revenue | OK | 0001104659-26-033077, 0001104659-26-056760 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001104659-26-093773 |
| Current Ratio | 13.54x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $2.02 | Revenue / Diluted Shares | OK | 0001104659-26-033077, 0001104659-26-056760 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001104659-26-033077 |